将免疫检查点抑制剂 (ICI) 治疗的黑色素瘤患者的早期 FDG PET/CT 与 ctDNA 相关联
使用免疫检查点抑制剂治疗的晚期黑色素瘤患者的早期间隔 18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描 (PET/CT) 与循环肿瘤 DNA (ctDNA) 之间的相关性
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
研究概览
地位
详细说明
This is a pilot, prospective, observational study to estimate the degree to which baseline and early interval 18F-FDG PET/CT imaging within 3-4 weeks of ICI therapy initiation can accurately correlate with ctDNA level trends, predict clinical response, onset of immune-related adverse events, and survival outcomes in advanced stage melanoma patients.
Primary Objective
• To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks correlates with ctDNA level changes in advanced melanoma patients.
Secondary Objectives
- To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks predicts clinical efficacy at standard disease assessment time points in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT predicts development of clinical irAEs in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts progression-free survival (PFS) in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts overall survival (OS) in advanced melanoma patients.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- University of Wisconsin Hospitals and Clinics (UWHC)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
24 participants with advanced stage III or stage IV melanoma with measurable disease who are deemed appropriate for treatment with ICI therapy.
描述
Inclusion Criteria:
- Willing to provide informed consent.
- Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned.
- Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy.
- Individuals at least 18 years of age.
- Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.
- Willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria:
- Not able to receive treatment with ICI therapy
- Use of investigational drugs, biologics, or devices within 30 days prior to enrollment.
- Women who are pregnant, lactating, or planning on becoming pregnant during the study.
- Not suitable for study participation due to other reasons at the discretion of the investigators.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
使用免疫检查点抑制剂的晚期黑色素瘤患者
|
research scan 3-4 weeks after start of immunotherapy
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in ctDNA level from baseline to 3-4 week after the start of therapy
大体时间:baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
ctDNA level is monitored per standard of care in this population, data from chart review. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
大体时间:baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy reported as SUV max. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Correlation between ctDNA level change and 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
大体时间:baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy with quantitative changes in ctDNA levels at baseline and at 3-4 weeks after starting ICI therapy. Pearson's or Rank's correlation coefficient will be used to measure the baseline measures for ctDNA level trends and PET/CT responses and for those measurements at 3-4 weeks. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Diagnostic Accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition as measured by Area under the Curve
大体时间:baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Receiver-operator curve analysis will be performed to determine the diagnostic accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition (area under the curve). |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate (ORR)
大体时间:up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. ORR is Partial Response (PR) plus Complete Response (CR). |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Disease Control Rate (DCR)
大体时间:up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. DCR is Stable Disease (SD) plus PR plus CR. |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Change in Standard Uptake Value (SUV) metrics with onset of Immune Related Adverse Events (irAE)
大体时间:up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate organ-level FDG uptake and changes from the baseline and early 18F-FDG PET/CT assessment with onset of first, second, and third symptomatic irAE per CTCAE v5.0 |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Progression Free Survival (PFS)
大体时间:up to 3 years after the first ICI dose (approximately 3 years on study)
|
PFS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and PFS
大体时间:up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT treatment response with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and PFS
大体时间:up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Overall Survival (OS)
大体时间:up to 3 years after the first ICI dose (approximately 3 years on study)
|
OS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and OS
大体时间:up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT response assessment with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and OS
大体时间:up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
合作者和调查者
调查人员
- 首席研究员:Vincent Ma, MD、University of Wisconsin, Madison
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2023-1089
- A534260 (其他标识符:UW Madison)
- UW23077 (其他标识符:UWCCC)
- Protocol Version 2/12/2024 (其他标识符:UW Madison)
- NCI-2023-11059 (注册表标识符:NCI Trial ID)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.